Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
LBPH

LBPH - Longboard Pharmaceuticals, Inc. Stock Price, Fair Value and News

18.53USD-1.42 (-7.12%)Market Closed

Market Summary

LBPH
USD18.53-1.42
Market Closed
-7.12%

LBPH Stock Price

View Fullscreen

LBPH RSI Chart

LBPH Valuation

Market Cap

720.4M

Price/Earnings (Trailing)

-12.43

Price/Free Cashflow

-13.61

LBPH Price/Earnings (Trailing)

LBPH Profitability

Return on Equity

-18.47%

Return on Assets

-17.69%

Free Cashflow Yield

-7.35%

LBPH Fundamentals

LBPH Earnings

Earnings (TTM)

-58.0M

Earnings Growth (Yr)

-30.81%

Earnings Growth (Qtr)

0.31%

Breaking Down LBPH Revenue

Last 7 days

5.6%

Last 30 days

-12.3%

Last 90 days

-4.1%

Trailing 12 Months

138.8%

How does LBPH drawdown profile look like?

LBPH Financial Health

Current Ratio

31.43

LBPH Investor Care

Shares Dilution (1Y)

69.27%

Diluted EPS (TTM)

-2.25

Tracking the Latest Insider Buys and Sells of Longboard Pharmaceuticals, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 08, 2024
kaye randall
acquired
-
-
17,920
cmo
Feb 08, 2024
roberts brandi
acquired
-
-
15,090
cfo
Jan 25, 2024
arena pharmaceuticals inc
sold
-96,479,600
24.25
-3,978,540
-
Mar 16, 2021
arena pharmaceuticals inc
acquired
-
-
138,000
-

1–4 of 4

Which funds bought or sold LBPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
88.43
54,105,000
63,514,800
0.29%
May 17, 2024
Ikarian Capital, LLC
reduced
-99.98
-5,901,060
5,098
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
748
454,274
469,735
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
400,421
400,421
-%
May 16, 2024
AWM Investment Company, Inc.
new
-
4,568,790
4,568,790
0.60%
May 15, 2024
Cubist Systematic Strategies, LLC
new
-
495,701
495,701
-%
May 15, 2024
DEUTSCHE BANK AG\
new
-
242,309
242,309
-%
May 15, 2024
Driehaus Capital Management LLC
new
-
8,391,000
8,391,000
0.08%
May 15, 2024
STATE STREET CORP
added
117
12,208,000
14,007,800
-%
May 15, 2024
WELLINGTON MANAGEMENT GROUP LLP
new
-
46,145,400
46,145,400
0.01%

1–10 of 46

Are Funds Buying or Selling LBPH?

Are funds buying LBPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LBPH
No. of Funds

Unveiling Longboard Pharmaceuticals, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
fmr llc
-
0
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
7.6%
1,626,982
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
3.8%
825,000
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
4.79%
1,027,679
SC 13G/A
Feb 13, 2024
prosight management, lp
0.0%
0
SC 13G/A
Feb 13, 2024
hbm healthcare investments (cayman) ltd.
0%
0
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 30, 2024
farallon capital partners, l.p.
5.5%
1,205,990
SC 13G/A
Jan 29, 2024
pfizer inc
0.00%
0
SC 13D/A
Jan 26, 2024
integrated core strategies (us) llc
0.0%
6,603
SC 13G/A

Recent SEC filings of Longboard Pharmaceuticals, Inc.

View All Filings
Date Filed Form Type Document
Jun 10, 2024
8-K
Current Report
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
8-K
Current Report
May 02, 2024
10-Q
Quarterly Report
May 02, 2024
8-K
Current Report
Apr 15, 2024
8-K
Current Report

Peers (Alternatives to Longboard Pharmaceuticals, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Longboard Pharmaceuticals, Inc. News

Latest updates
MarketBeat44 hours ago

Longboard Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets546.3%32851.0059.0066.0080.0071.0081.0091.0010110911612112456.00
  Current Assets544.0%32350.0058.0066.0079.0070.0080.0090.0010010811512112455.00
    Cash Equivalents279.6%54.0014.0024.0020.0025.0011.0019.0028.0035.0066.0075.0091.0012155.00
  Net PPE-25.0%0.000.000.000.000.000.000.000.000.000.000.00---
  Current Liabilities5.3%10.0010.007.008.007.009.008.008.007.005.004.003.004.003.00
Shareholder's Equity666.6%31441.0052.0058.0072.0061.0072.0083.0094.00103112117120-
  Retained Earnings-10.6%-155-140-125-112-97.60-86.14-74.80-63.20-51.79-42.20-33.42-27.10-20.10-14.40
  Additional Paid-In Capital158.7%47018217817117014814814714614614514514012.00
Shares Outstanding52.1%34.0022.0021.0021.0020.0014.0017.0017.0017.0013.0014.0017.00--
Float----148---52.00---117,500--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Cashflow From Operations-37.6%-15,177-11,028-13,289-13,454-13,097-9,671-9,853-8,514-10,025-5,675-6,134-5,150-7,746-1,459-1,041-903-39.00
  Share Based Compensation103.4%1,7498608568416975927956995715845385123337,36049855595.00
Cashflow From Investing-14693.0%-230,919-1,56111,7497,9626,0832,1458821,193-21,284--------
Cashflow From Financing9415.1%286,4043,0105,946-12521,360-444-----2.003,17273,281---39.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LBPH Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 13,170$ 8,530
General and administrative4,9403,432
Total operating expenses18,11011,962
Loss from operations(18,110)(11,962)
Interest income, net3,133516
Other expense(9)(10)
Net loss$ (14,986)$ (11,456)
Net loss per share, basic$ (0.42)$ (0.56)
Net loss per share, diluted$ (0.42)$ (0.56)
Weighted-average shares outstanding, basic35,321,79420,409,794
Weighted-average shares outstanding, diluted35,321,79420,409,794
Comprehensive loss:  
Net loss$ (14,986)$ (11,456)
Unrealized gain (loss) on short-term investments(288)271
Comprehensive loss$ (15,274)$ (11,185)

LBPH Balance Sheet

2024-03-31
Condensed Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 54,395$ 14,331
Short-term Investments266,64834,167
Prepaid expenses and other current assets2,3981,723
Total current assets323,44150,221
Right-of-use assets3,977472
Property and equipment34
Other long-term assets2440
Total assets327,66550,697
Current liabilities:  
Accounts payable1,0451,001
Accrued research and development expenses7,3044,556
Accrued compensation and related expenses1,0543,374
Accrued other expenses572368
Right-of-use liabilities, current portion315475
Total current liabilities10,2909,774
Right-of-use liabilities, net of current portion3,6670
Commitments and contingencies (see Note 9)
Stockholders' equity:  
Preferred Stock, Value, Issued00
Common Stock, Value, Issued32
Additional paid-in-capital469,621181,563
Accumulated other comprehensive loss(366)(78)
Accumulated deficit(155,550)(140,564)
Total stockholders' equity313,70840,923
Total liabilities and stockholders' equity327,66550,697
Non-Voting Common Stock [Member]  
Stockholders' equity:  
Common Stock, Value, Issued
LBPH
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
 CEO
 WEBSITElongboardpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES32

Longboard Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Longboard Pharmaceuticals, Inc.? What does LBPH stand for in stocks?

LBPH is the stock ticker symbol of Longboard Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Longboard Pharmaceuticals, Inc. (LBPH)?

As of Fri Jun 14 2024, market cap of Longboard Pharmaceuticals, Inc. is 720.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LBPH stock?

You can check LBPH's fair value in chart for subscribers.

What is the fair value of LBPH stock?

You can check LBPH's fair value in chart for subscribers. The fair value of Longboard Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Longboard Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LBPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Longboard Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether LBPH is over valued or under valued. Whether Longboard Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Longboard Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LBPH.